A Phase 3 interventional study of AC-170 0.24% and AC-170 0% in Allergic Conjunctivitis, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2017-11-07.
Sponsored by Aciex Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 46th largest by enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2012, is one of 34 in phase 3, and was the 47th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 91 is close to the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Aciex Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.
Aciex Therapeutics, Inc. has 6 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC) model.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AC-170 0.24%
Drug: AC-170 0%
1 drop in each eye at 2 separate times during a 14 day period
1 drop in each eye at 2 separate times during a 14 day period
Ocular Itching at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
Time frame: 3, 5, 7 minutes post-CAC
Ocular Itching at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
Time frame: 3, 5, 7 minutes post-CAC
Conjunctival Redness at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Conjunctival Redness at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ciliary Redness at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ciliary Redness at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Episcleral Redness at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Episcleral Redness at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Chemosis at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Chemosis at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Eyelid Swelling at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Eyelid Swelling at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Tearing at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Tearing at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Rhinorrhea at Duration of Action (16 Hours +1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Rhinorrhea at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Pruritis at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ear or Palate Pruritis at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Ear or Palate Pruritis at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Congestion at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Nasal Congestion at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Duration of Action (16 Hours + 1 Hour Post-dose)
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Number of Participants With At Least One of the Nasal Symptoms Present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) at Onset of Action (15 Minutes Post-dose)
A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.
Time frame: 7, 15, 20 minutes post-CAC
Tolerability of Study Medication at Visit 3A
Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
Time frame: upon instillation, 1 minute and 2 minutes post instillation
Subjects were recruited from three sites in the US.
| Milestone | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Started | 46 | 45 |
| Completed | 44 | 45 |
| Not completed | 2 | 0 |
A treatment efficacy Conjunctival Allergen Challenge (CAC) was performed 16 hours + 1 hour after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 3 minutes post-CAC | 1.71 ± 0.886 | 2.34 ± 0.720 |
| 5 minutes post-CAC | 1.88 ± 0.910 | 2.50 ± 0.644 |
| 7 minutes post-CAC | 1.76 ± 0.944 | 2.22 ± 0.875 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 3 minutes post-CAC | 0.71 ± 0.638 | 2.18 ± 0.979 |
| 5 minutes post-CAC | 1.01 ± 0.691 | 2.31 ± 0.980 |
| 7 minutes post-CAC | 1.00 ± 0.783 | 2.10 ± 0.998 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 1.72 ± 0.771 | 1.94 ± 0.796 |
| 15 minutes post-CAC | 1.96 ± 0.777 | 2.02 ± 0.788 |
| 20 minutes post-CAC | 1.92 ± 0.780 | 1.98 ± 0.759 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 2.02 ± 0.728 | 2.05 ± 0.714 |
| 15 minutes post-CAC | 2.23 ± 0.667 | 2.13 ± 0.736 |
| 20 minutes post-CAC | 2.28 ± 0.644 | 2.18 ± 0.762 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 1.54 ± 0.786 | 1.82 ± 0.832 |
| 15 minutes post-CAC | 1.77 ± 0.825 | 1.96 ± 0.756 |
| 20 minutes post-CAC | 1.72 ± 0.821 | 1.93 ± 0.771 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 1.64 ± 0.810 | 1.90 ± 0.645 |
| 15 minutes post-CAC | 1.85 ± 0.789 | 1.99 ± 0.769 |
| 20 minutes post-CAC | 1.95 ± 0.806 | 2.06 ± 0.767 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 1.72 ± 0.719 | 1.94 ± 0.798 |
| 15 minutes post-CAC | 1.94 ± 0.781 | 2.07 ± 0.775 |
| 20 minutes post-CAC | 1.89 ± 0.768 | 2.03 ± 0.764 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 1.88 ± 0.804 | 1.96 ± 0.725 |
| 15 minutes post-CAC | 2.10 ± 0.791 | 2.10 ± 0.793 |
| 20 minutes post-CAC | 2.20 ± 0.758 | 2.16 ± 0.778 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.49 ± 0.461 | 0.70 ± 0.550 |
| 15 minutes post-CAC | 0.71 ± 0.605 | 1.01 ± 0.693 |
| 20 minutes post-CAC | 0.76 ± 0.605 | 1.05 ± 0.802 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.74 ± 0.501 | 0.97 ± 0.702 |
| 15 minutes post-CAC | 1.12 ± 0.685 | 1.42 ± 0.895 |
| 20 minutes post-CAC | 1.22 ± 0.736 | 1.53 ± 0.950 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.7 ± 0.73 | 1.1 ± 0.67 |
| 15 minutes post-CAC | 1.0 ± 0.89 | 1.3 ± 0.88 |
| 20 minutes post-CAC | 1.0 ± 0.97 | 1.2 ± 0.95 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.6 ± 0.65 | 0.9 ± 0.75 |
| 15 minutes post-CAC | 0.8 ± 0.74 | 1.1 ± 0.76 |
| 20 minutes post-CAC | 0.8 ± 0.79 | 1.1 ± 0.89 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.8 ± 0.69 | 1.1 ± 1.08 |
| 15 minutes post-CAC | 0.9 ± 0.89 | 1.2 ± 1.16 |
| 20 minutes post-CAC | 0.9 ± 0.98 | 1.1 ± 1.25 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.4 ± 0.57 | 1.0 ± 0.88 |
| 15 minutes post-CAC | 0.6 ± 0.87 | 0.8 ± 0.84 |
| 20 minutes post-CAC | 0.7 ± 0.88 | 0.8 ± 0.97 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.7 ± 0.89 | 1.4 ± 1.11 |
| 15 minutes post-CAC | 1.0 ± 1.03 | 1.3 ± 1.14 |
| 20 minutes post-CAC | 1.1 ± 1.10 | 1.4 ± 1.22 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.3 ± 0.64 | 1.1 ± 0.97 |
| 15 minutes post-CAC | 0.5 ± 0.73 | 1.0 ± 1.04 |
| 20 minutes post-CAC | 0.6 ± 0.82 | 1.0 ± 1.04 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.4 ± 0.72 | 1.0 ± 1.14 |
| 15 minutes post-CAC | 0.8 ± 1.03 | 1.0 ± 1.14 |
| 20 minutes post-CAC | 0.8 ± 0.95 | 1.1 ± 1.20 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.3 ± 0.53 | 0.7 ± 0.92 |
| 15 minutes post-CAC | 0.3 ± 0.59 | 0.8 ± 0.97 |
| 20 minutes post-CAC | 0.5 ± 0.73 | 0.7 ± 0.85 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.4 ± 0.69 | 1.0 ± 1.24 |
| 15 minutes post-CAC | 1.0 ± 1.13 | 1.3 ± 1.41 |
| 20 minutes post-CAC | 1.2 ± 1.16 | 1.5 ± 1.42 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.3 ± 0.51 | 1.0 ± 1.24 |
| 15 minutes post-CAC | 0.5 ± 0.66 | 1.1 ± 1.27 |
| 20 minutes post-CAC | 0.6 ± 0.69 | 1.0 ± 1.20 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.9 ± 0.94 | 1.3 ± 1.05 |
| 15 minutes post-CAC | 1.1 ± 1.04 | 1.5 ± 1.16 |
| 20 minutes post-CAC | 1.2 ± 1.15 | 1.4 ± 1.14 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 0.3 ± 0.60 | 1.0 ± 0.89 |
| 15 minutes post-CAC | 0.7 ± 0.86 | 1.2 ± 1.01 |
| 20 minutes post-CAC | 0.8 ± 1.10 | 1.2 ± 1.05 |
A treatment efficacy CAC was performed 16 hours + 1 hour after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.
| %participants with at least 1 nasal symp | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 68.9 | 84.4 |
| 15 minutes post-CAC | 80.0 | 88.9 |
| 20 minutes post-CAC | 86.7 | 93.3 |
A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.
| %participants with at least 1 nasal symp | AC-170 0.24% | AC-170 0% |
|---|---|---|
| 7 minutes post-CAC | 50 | 82.2 |
| 15 minutes post-CAC | 65.9 | 86.7 |
| 20 minutes post-CAC | 70.5 | 84.4 |
Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.
| units on a scale | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Upon instillation | 1.2 ± 1.44 | 0.9 ± 1.27 |
| 1 minute post-instillation | 2.4 ± 2.37 | 0.6 ± 0.80 |
| 2 minutes post-instillation | 2.1 ± 2.29 | 0.6 ± 0.78 |
Collected over Adverse events were collected through the duration of the study, over the course of approximately 3 months. All subjects who received study medication were evaluable for the safety analysis.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AC-170 0.24% | — | 0/46 (0%) | 1/46 (2.2%) |
| AC-170 0% | — | 0/45 (0%) | 5/45 (11.1%) |
| Event | AC-170 0.24% | AC-170 0% |
|---|---|---|
| Visual acuity reducedEye disorders | 0/46 | 1/45 |
| HordeolumInfections and infestations | 0/46 | 1/45 |
| NasopharyngitisInfections and infestations | 0/46 | 1/45 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/46 | 1/45 |
| PruritusSkin and subcutaneous tissue disorders | 0/46 | 1/45 |
| Conjunctival haemorrhageEye disorders | 1/46 | 0/45 |
| Age, Continuous(years) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| Mean | 36.6 ± 14.95 | 38.1 ± 14.08 | 37.4 ± 14.47 |
| Sex: Female, Male(Participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| Female | 24 | 28 | 52 |
| Male | 22 | 17 | 39 |
| Ethnicity (NIH/OMB)(Participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 13 | 25 |
| Not Hispanic or Latino | 34 | 32 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| American Indian or Alaska Native | 7 | 7 | 14 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 9 | 5 | 14 |
| White | 30 | 33 | 63 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | AC-170 0.24% | AC-170 0% | Total |
|---|---|---|---|
| United States | 46 | 45 | 91 |
The record gives a start of Mar 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2017, 5 years 4 months after primary completion. A results delay was requested in Apr 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cetirizine
Aciex Therapeutics, Inc.